Roger Jeffs, Ph.D.

Roger Jeffs, Ph.D.

DirectoratLiquidia· In proxies 2022–2025

Pay in FY2025+14% from the year before · Liquidia stock +193.3% the same year

Roger Jeffs, Ph.D. was paid $7.7M in FY2025 (Dec), up 14%. Liquidia stock rose 193.3% that year.

Pay$100 in the stock at the end of FY21 → $708
Pay is from the Summary Compensation Table of each Liquidia proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Axsome TherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. LiquidiaPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role +898%
  3. Albireo Pharma, Axovant Gene Therapies, Dova PharmaceuticalsPublic company
    • Director? – PresentNo stock prices for these years
  4. Albireo Pharma, Inc.Public company
    • Director? – PresentNo stock prices for these years
  5. Axovant Gene TherapiesPublic company
    • Director? – PresentNo stock prices for these years
  6. Dova PharmaceuticalsPublic company
    • Director? – PresentNo stock prices for these years
  7. Sangamo TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?